Dupixent

Dupixent

dupilumab

Manufacturer:

Sanofi

Distributor:

DCH Auriga - Healthcare
/
Four Star
Concise Prescribing Info
Contents
Dupilumab
Indications/Uses
Treatment of moderate to severe atopic dermatitis in adults & adolescents ≥12 yr who are candidates for systemic therapy; severe atopic dermatitis in childn 6-11 yr who are candidates for systemic therapy. Add-on maintenance treatment for severe asthma w/ type 2 inflammation characterised by raised blood eosinophils &/or raised fraction of exhaled nitric oxide (FeNO) in adults & adolescents ≥12 yr who are inadequately controlled w/ high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment. 300 mg: Add-on therapy w/ intranasal corticosteroids for the treatment of adults w/ severe chronic rhinosinusitis w/ nasal polyposis (CRSwNP) for whom therapy w/ systemic corticosteroids &/or surgery do not provide adequate disease control.
Dosage/Direction for Use
SC Atopic dermatitis Adult Initially 600 mg (two 300-mg inj consecutively administered at different inj site), followed by 300 mg every other wk. Adolescent 12-17 yr, weighing ≥60 kg Initially 600 mg, followed by 300 mg every other wk, <60 kg Initially 400 mg (two 200-mg inj consecutively administered at different inj site), followed by 200 mg every other wk. Childn 6-11 yr, weighing ≥60 kg Initially 600 mg, followed by 300 mg every other wk, 15 to <60 kg Initially 300 mg on day 1, followed by 300 mg on day 15. Subsequent doses: 300 mg every 4 wk, starting 4 wk after day 15 dose. Dose may be increased to 200 mg every other wk based on physician's assessment. Asthma Adult & adolescent ≥12 yr Initially 400 mg, followed by 200 mg every other wk. Patient w/ severe asthma & who are on oral corticosteroids; patient w/ severe asthma & co-morbid moderate to severe atopic dermatitis; adult w/ co-morbid severe chronic rhinosinusitis w/ nasal polyposis Initially 600 mg, followed by 300 mg every other wk. CRSwNP Adult Initially 300 mg, followed by 300 mg every other wk.
Contraindications
Special Precautions
Should not be used to treat acute asthma symptoms or acute exacerbations; acute bronchospasms or status asthmaticus. Discontinue immediately if systemic hypersensitivity reaction (immediate or delayed) occurs. Eosinophilic conditions in adult asthma patients. Patients w/ pre-existing helminth infections should be treated before initiating dupilumab. Conjunctivitis & keratitis-related events, predominantly in atopic dermatitis patients. Atopic dermatitis or CRSwNP patients w/ comorbid asthma. Do not concurrently give live & live attenuated vaccines. Patients w/ hepatic impairment or severe renal impairment. Pregnancy & lactation. Childn <12 yr w/ severe asthma. Childn <6 yr w/ atopic dermatitis. Childn weighing <15 kg.
Adverse Reactions
Inj site reactions (including erythema, oedema, pruritus, pain, swelling); conjunctivitis, oral herpes; eosinophilia; conjunctivitis allergic; arthralgia.
MIMS Class
Antiasthmatic & COPD Preparations / Nasal Decongestants & Other Nasal Preparations / Other Dermatologicals
ATC Classification
D11AH05 - dupilumab ; Belongs to the class of agents for atopic dermatitis, excluding corticosteroids. Used in the treatment of atopic dermatitis.
Presentation/Packing
Form
Dupixent soln for inj 200 mg/1.14 mL
Packing/Price
2 × 1's
Form
Dupixent soln for inj 300 mg/2 mL
Packing/Price
2 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in